Osteoblasts/bone marrow stromal cells express ODF on the surface of osteoclast precursors. The interaction of ODF with RANK (receptor activator of NF-?B) transduces a signal to initiate osteoclast differentiation via the NF-?B pathway. The involvement of ODF in osteoclastogenesis is supported by the fact that the soluble decoy receptor OPG (osteoprotegerin)/OCIF (osteoclastogenesis inhibitory factor) blocks the survival and activity of osteoclasts induced by osteoblasts/stromal cells or sODF. This suggests that the ODF interaction with RANK is important in regulating the number of osteoclasts and may be a therapeutic target for bone metabolism disorders including arthritis, osteoporosis and orthopedic osteolysis. TNF-a has also been implicated in inflammatory bone diseases and transduces signals through its two receptors, leading to the activation of NF-?B. This study examined both the ability of TNF-a to stimulate osteoclast differentiation and the pathway involved in mediating the induction. To determine whether and how TNF-a is able to induce osteoclastogenesis in bone marrow macrophages (BMMFs).
Significant findings
After three days, murine bone marrow cultures were composed of macrophages as assessed by immunohistochemical staining. These BMMfs were induced to form multinucleated TRAP 
Comments
This paper makes the very interesting observation, that tumor necrosis factor alpha (TNF-a) can induce osteoclast differentiation in vitro through a mechanism independent of ODF (osteoclast differentiation factor also known as RANKL [receptor activator of NF-?B ligand]). The idea of ODFindependent osteoclastogenesis is controversial since, in vivo, ODF appears to be absolutely required for osteoclastogenesis. However, the authors tested their hypothesis only in an in vitro culture system; in vivo work is needed to fully comprehend the nature of TNF-a and ODF signaling. Understanding the relationship between TNF-a and bone metabolism will lead to more effective therapeutics to treat inflammatory bone diseases such as arthritis, osteoporosis, and orthopedic osteolysis.
Methods
Murine bone marrow was isolated and the adherent cells were removed and cultured for three days in the presence of various cytokines and inhibitors. Osteoclastogenesis was measured by staining for tartrate-resistant acid phosphatase (TRAP) and counting the number of multinucleated TRAP + cells. BMMfs were characterized according to cell surface receptor mRNA expression by RT-PCR. Osteoclast function was assayed with a pit formation assay in which bone marrow cells were plated on dentine slices with macrophage colony stimulating factor (M-CSF) for six days and stained for TRAP or with hematoxylin. TRAP + cells and the number of resorption pits were counted. The survival of osteoclasts was determined by culturing with TNF-a, interleukin (IL)-1a, or sODF in the absence of M-CSF for three days then counting the number of TRAP + cells remaining.
